卵巢癌的免疫疗法
Immunotherapy in Ovarian Cancer.
作者信息
Wang Weimin, Liu Janice Rebecca, Zou Weiping
机构信息
Department of Surgery, University of Michigan School of Medicine, BSRB 5448, 109 Zina Pitcher Place, Ann Arbor, MI 48109-0669, USA.
Department of Obstetrics and Gynecology, University of Michigan School of Medicine, L4604 WH, 1500 East Medical Center, Ann Arbor, MI 48109, USA.
出版信息
Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5.
Abstract
The phenotype and functionalities of the major immune cell subsets including myeloid cells, macrophages, dendritic cells, and T cells are altered in the ovarian cancer microenvironment. Immunosuppressive networks including inhibitory B7 family members and regulatory T cell-associated adenosine pathway have been defined in human ovarian cancer. In this review, the authors integrate emerging information on immunosuppressive mechanisms and T cell phenotype and discuss strategies of immunotherapeutic and vaccine regimens. Finally, crucial points regarding design of immuno-oncology clinical trials are reviewed.
摘要
包括髓样细胞、巨噬细胞、树突状细胞和T细胞在内的主要免疫细胞亚群的表型和功能在卵巢癌微环境中会发生改变。人类卵巢癌中已确定了包括抑制性B7家族成员和调节性T细胞相关腺苷途径在内的免疫抑制网络。在这篇综述中，作者整合了关于免疫抑制机制和T细胞表型的最新信息，并讨论了免疫治疗和疫苗方案的策略。最后，对免疫肿瘤学临床试验设计的关键点进行了综述。
相似文献
1
Immunotherapy in Ovarian Cancer.卵巢癌的免疫疗法
Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5.
2
Immunotherapy in ovarian cancer.卵巢癌的免疫疗法。
Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.
3
New Approaches for Immune Directed Treatment for Ovarian Cancer.卵巢癌免疫导向治疗的新方法。
Curr Treat Options Oncol. 2016 Mar;17(3):14. doi: 10.1007/s11864-016-0389-1.
4
Emerging immunotherapies in ovarian cancer.卵巢癌中的新兴免疫疗法。
Discov Med. 2015 Sep;20(109):97-109.
5
Immunity and immune suppression in human ovarian cancer.人卵巢癌中的免疫与免疫抑制。
Immunotherapy. 2011 Apr;3(4):539-56. doi: 10.2217/imt.11.20.
6
Targeted immune therapy of ovarian cancer.卵巢癌的靶向免疫治疗
Cancer Metastasis Rev. 2015 Mar;34(1):53-74. doi: 10.1007/s10555-014-9540-2.
7
Opportunities in immunotherapy of ovarian cancer.卵巢癌免疫治疗的机遇
Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i11-i15. doi: 10.1093/annonc/mdw084.
8
Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.靶向肿瘤微环境中的髓样细胞可增强小鼠上皮性卵巢癌疫苗的疗效。
Oncotarget. 2015 May 10;6(13):11310-26. doi: 10.18632/oncotarget.3597.
9
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.靶向骨髓微环境中的免疫龛：多发性骨髓瘤免疫治疗的兴起。
Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834.
10
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.免疫疗法在靶向多发性骨髓瘤骨髓微环境中的作用：一种不断发展的治疗策略。
Pharmacotherapy. 2017 Jan;37(1):129-143. doi: 10.1002/phar.1871. Epub 2017 Jan 6.
引用本文的文献
1
Immune pathway through endometriosis to ovarian cancer.通过子宫内膜异位症发展为卵巢癌的免疫途径。
World J Clin Oncol. 2024 Apr 24;15(4):496-522. doi: 10.5306/wjco.v15.i4.496.
2
Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions.宫颈癌和子宫内膜癌的免疫治疗：现状与未来方向
Life (Basel). 2024 Mar 6;14(3):344. doi: 10.3390/life14030344.
3
Unlocking the 'ova'-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment.解锁“卵母细胞”潜能：免疫疗法在塑造卵巢癌治疗未来中的作用。
Med Oncol. 2024 Jan 29;41(3):67. doi: 10.1007/s12032-023-02281-6.
4
Deep learning-based segmentation of multisite disease in ovarian cancer.基于深度学习的卵巢癌多部位病变分割。
Eur Radiol Exp. 2023 Dec 7;7(1):77. doi: 10.1186/s41747-023-00388-z.
5
The synergistic effect of EMT regulators and m6A modification on prognosis-related immunological signatures for ovarian cancer.EMT 调节剂和 m6A 修饰物对卵巢癌预后相关免疫特征的协同作用。
Sci Rep. 2023 Sep 8;13(1):14872. doi: 10.1038/s41598-023-41554-y.
6
Identification of fatty acid signature to predict prognosis and guide clinical therapy in patients with ovarian cancer.鉴定脂肪酸特征以预测卵巢癌患者的预后并指导临床治疗。
Front Oncol. 2022 Oct 4;12:979565. doi: 10.3389/fonc.2022.979565. eCollection 2022.
7
Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations.化疗耐药癌细胞系的特征在于迁移、氨基酸代谢、蛋白质分解代谢和IFN1信号传导紊乱。
Cancers (Basel). 2022 Jun 2;14(11):2763. doi: 10.3390/cancers14112763.
8
Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers.卵巢癌肿瘤突变负荷相关免疫预后特征的开发与验证
Front Genet. 2022 Jan 11;12:688207. doi: 10.3389/fgene.2021.688207. eCollection 2021.
9
MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer.miR-200b 在血浆来源的外泌体中上调，并通过促进卵巢癌细胞中巨噬细胞 M2 极化发挥癌基因作用。
J Ovarian Res. 2021 Jun 2;14(1):74. doi: 10.1186/s13048-021-00826-9.
10
A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.一种新型小分子 LLL12B 抑制 STAT3 信号通路并增强卵巢癌细胞对紫杉醇和顺铂的敏感性。
PLoS One. 2021 Apr 28;16(4):e0240145. doi: 10.1371/journal.pone.0240145. eCollection 2021.
本文引用的文献
1
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
2
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.LSD1 消融可刺激抗肿瘤免疫并启用检查点阻断。
Cell. 2018 Jul 26;174(3):549-563.e19. doi: 10.1016/j.cell.2018.05.052. Epub 2018 Jun 21.
3
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.有氧糖酵解通过三阴性乳腺癌中特定的 CEBPB 异构体控制髓源性抑制细胞和肿瘤免疫。
Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24.
4
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.基于 NY-ESO-1 的癌症免疫治疗：当前观点。
Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018.
5
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.诱导卵巢癌细胞新抗原特异性细胞毒性 T 细胞和构建 T 细胞受体工程化 T 细胞。
Clin Cancer Res. 2018 Nov 1;24(21):5357-5367. doi: 10.1158/1078-0432.CCR-18-0142. Epub 2018 May 2.
6
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.个体化癌症疫苗能有效调动卵巢癌抗肿瘤 T 细胞免疫。
Sci Transl Med. 2018 Apr 11;10(436). doi: 10.1126/scitranslmed.aao5931.
7
Dendritic Cell-Based Immunotherapy for Solid Tumors.基于树突状细胞的实体瘤免疫疗法
Transl Oncol. 2018 Jun;11(3):686-690. doi: 10.1016/j.tranon.2018.03.007. Epub 2018 Apr 6.
8
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
9
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.叶酸受体α肽疫苗在乳腺癌和卵巢癌患者中产生免疫应答。
Clin Cancer Res. 2018 Jul 1;24(13):3014-3025. doi: 10.1158/1078-0432.CCR-17-2499. Epub 2018 Mar 15.
10
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.宿主表达 PD-L1 决定 PD-L1 通路阻断介导的肿瘤消退疗效。
J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16.
Zotero 插件